Prognostic significance of the presence of tertiary Gleason grade 5 in robot-assisted radical prostatectomy specimens in Japanese patients with clinically localized prostate cancer.


Journal

Japanese journal of clinical oncology
ISSN: 1465-3621
Titre abrégé: Jpn J Clin Oncol
Pays: England
ID NLM: 0313225

Informations de publication

Date de publication:
01 Mar 2019
Historique:
received: 21 08 2018
revised: 12 02 2018
accepted: 07 12 2018
pubmed: 17 1 2019
medline: 18 10 2019
entrez: 17 1 2019
Statut: ppublish

Résumé

The aim of this study was to study the prognostic significance of tertiary Gleason grade (TGG) 5 in patients with clinically localized prostate cancer treated with robot-assisted radical prostatectomy (RARP). A total of 600 Japanese patients who underwent RARP for clinical stage T1-3N0M0 prostate cancer were evaluated. TGG5 was evaluated according to the International Society of Urological Pathology criterion. Cox hazard regression was used to evaluate the prognostic significance of prostate-specific antigen and pathological features in RARP specimens. Of the 600 RARP specimens, 92 (15%) had TGG5. TGG5 component was found in 30 (10%) of 287 cases with Gleason score (GS) 3 + 4, 55 (37%) of 149 cases with GS 4 + 3 and 7 (17%) of 40 cases with GS 4 + 4. There were no significant differences in pathological stage and surgical margin status between GS 3 + 4 with and without TGG5, as well as between GS 4 + 4 with and without TGG5. Of the 600 patients, 92 (15%) patients had biochemical recurrence (BCR) after surgery, with a median follow-up period of 42 (3-104) months. There were no differences in 5-year BCR-free survival rates between patients with GS 3 + 4 with and without TGG5 (92 vs. 100%, P = 0.16), as well as between patients with GS 4 + 3 with and without TGG5 (79 vs. 71%, P = 0.30). Similarly, there were no differences in 3-year BCRFS rates between patients with GS 4 + 4 with and without TGG5 (80 vs. 71%, P = 0.38). In our population, the presence of TGG5 in RARP specimens had no strong impact on pathological and prognostic outcomes.

Sections du résumé

BACKGROUND BACKGROUND
The aim of this study was to study the prognostic significance of tertiary Gleason grade (TGG) 5 in patients with clinically localized prostate cancer treated with robot-assisted radical prostatectomy (RARP).
METHODS METHODS
A total of 600 Japanese patients who underwent RARP for clinical stage T1-3N0M0 prostate cancer were evaluated. TGG5 was evaluated according to the International Society of Urological Pathology criterion. Cox hazard regression was used to evaluate the prognostic significance of prostate-specific antigen and pathological features in RARP specimens.
RESULTS RESULTS
Of the 600 RARP specimens, 92 (15%) had TGG5. TGG5 component was found in 30 (10%) of 287 cases with Gleason score (GS) 3 + 4, 55 (37%) of 149 cases with GS 4 + 3 and 7 (17%) of 40 cases with GS 4 + 4. There were no significant differences in pathological stage and surgical margin status between GS 3 + 4 with and without TGG5, as well as between GS 4 + 4 with and without TGG5. Of the 600 patients, 92 (15%) patients had biochemical recurrence (BCR) after surgery, with a median follow-up period of 42 (3-104) months. There were no differences in 5-year BCR-free survival rates between patients with GS 3 + 4 with and without TGG5 (92 vs. 100%, P = 0.16), as well as between patients with GS 4 + 3 with and without TGG5 (79 vs. 71%, P = 0.30). Similarly, there were no differences in 3-year BCRFS rates between patients with GS 4 + 4 with and without TGG5 (80 vs. 71%, P = 0.38).
CONCLUSIONS CONCLUSIONS
In our population, the presence of TGG5 in RARP specimens had no strong impact on pathological and prognostic outcomes.

Identifiants

pubmed: 30649377
pii: 5288279
doi: 10.1093/jjco/hyy194
doi:

Substances chimiques

Biomarkers, Tumor 0
Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

276-280

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Naohiro Kamoda (N)

Department of Urology, Tokyo Medical University, Tokyo, Japan.

Makoto Ohori (M)

Department of Urology, Tokyo Medical University, Tokyo, Japan.

Yosuke Hirasawa (Y)

Department of Urology, Tokyo Medical University, Tokyo, Japan.

Rie Inoue (R)

Anatomic Pathology, Tokyo Medical University, Tokyo, Japan.

Takeshi Hashimoto (T)

Department of Urology, Tokyo Medical University, Tokyo, Japan.

Naoya Satake (N)

Department of Urology, Tokyo Medical University, Tokyo, Japan.

Tatsuo Gondo (T)

Department of Urology, Tokyo Medical University, Tokyo, Japan.

Yoshihiro Nakagami (Y)

Department of Urology, Tokyo Medical University, Tokyo, Japan.

Toshitaka Nagao (T)

Anatomic Pathology, Tokyo Medical University, Tokyo, Japan.

Yoshio Ohno (Y)

Department of Urology, Tokyo Medical University, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH